Background: Previous study has confirmed that the occurrence of Wnt pathway activation is associated with risk of non-small-cell lung cancer recurrence. However, whether the pharmacologic blocking of the Wnt signaling pathway could provide therapeutic possibility remains unknown. The aim of the present study was to evaluate the therapeutic functions of the Wnt signaling pathway inhibitor pyrvinium pamoate (PP) on lung cancer stem cells (LCSCs) in vitro. Methods: Colony formation and sphere culture were performed to enrich LCSCs from three lung cancer cell lines: PC9, SPC-A1, and A549. After confirming stemness by immunofluorescence, PP was employed for cell viability assay by comparison with three other kinds of Wnt signaling inhibitor: salinomycin, ICG-001, and silibinin. The effect of PP on LCSCs was further verified by colony formation assay and gene expression analysis. Results: LCSCs were successfully generated by sphere culture from SPC-A1 and PC9 cells, but not A549 cells. Immunofluorescence assay showed that LCSCs could express pluripotent stem cell markers, including NANOG, Oct4, KLF5, and SOX2, and Wnt signaling pathway molecules β-catenin and MYC. Half-maximal inhibitory concentrations of PP on SPC-A1, PC9, and A549 were 10 nM, 0.44 nM, and 0.21 nM, respectively, which are much lower than those of salinomycin, ICG-001, and silibinin. Moreover, significantly decreased colony formation and downregulation of pluripotent stem cell signaling pathway were observed in lung cancer cells after treatment with PP. Conclusion: Wnt signaling inhibitor PP can inhibit proliferation of LCSCs, and the Wnt signaling pathway could be considered a promising therapeutic or interventional target in lung adenocarcinoma.
Introduction
Lung cancer, the second most common cancer type in humans, is the most common cause of cancer death in the whole world. In 2008, over 1.6 million people were confirmed with a new diagnosis of lung cancer, comprising approximately 15% of all newly diagnosed cancers, and 1.4 million people died from lung cancer, which was 18% of all cancer deaths. 1 Despite great efforts having been made to explore the therapeutic effect for lung adenocarcinoma, the clinical outcomes of lung adenocarcinoma remain poor in patients. Novel and effective therapies are urgently needed in the current situation.
Cancer stem cells (CSCs), which were initially reported in hematological malignancies, 2 are a rare population of phenotypically distinct cells displaying unlimited proliferation potential and self-renewal ability. The CSCs cells can also be differentiated and constituted the major tumor population of lung adenocarcinoma.
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As well as in hematological cancers, the presence of CSCs was also confirmed in several solid tumors, including lung cancer, 3 and they were proposed as new therapeutic targets for cancer treatment.
Lung CSCs (LCSCs), first described by Carney et al 4 were isolated from a variety of cell lines and tumor specimens. 5 Similar to other CSCs, LCSCs can express biomarkers, including CD44, CD133, and aldehyde dehydrogenase isoform 1 (ALDH1), 6 and exhibit properties of radioresistance, 7 chemoresistance, and sphere formation. 8 A previous study 6 confirmed that LCSCs are related to the high recurrence rates of lung adenocarcinoma in patients. Moreover, multiple signaling pathways, including those of epidermal growth factor receptor (EGFR), Hedgehog, and Notch, were found to be involved in the regulation of stemness of LCSCs. In 2010, Teng et al 9 found an activated Wnt/β-catenin pathway in lung cancer cell line A549, which upregulates the stem cell marker Oct4. Shapiro et al 10 further confirmed that the occurrence of Wnt pathway activation in stage I non-small-cell lung cancer patients was related to the risk of tumor recurrence. However, whether pharmacologic blocking of the Wnt signaling pathway acts as a therapeutic method remains unknown.
In this study, a US Food and Drug Administration (FDA)-approved antihelminthics drug targeting Wnt signaling, pyrvinium pamoate (PP), was used to examine the growth inhibition effect on LCSCs in vitro and to explore possible molecular mechanisms.
Materials and methods cell culture
Human lung cancer cell lines PC9, SPC-A1, and A549 were purchased from China Academy of Sciences (Shanghai, People's Republic of China). The above cells were cultured in RPMI-1640 or Dulbecco's Modified Eagle's Medium (DMEM) (Hyclone, Logan city, Utah, USA) containing 10% fetal bovine serum (FBS) (Hyclone). Penicillin (100 U/mL) and streptomycin (100 μg/mL) were added to the DMEM, and the resulting mixture was cultured in a 5% CO 2 incubator at 37°C.
sphere formation culture Cells were collected from colony formation assay (day 5) (described in Immunofluorescence graph) and suspended in serum-free DMEM/F12 containing 1/100 v/v insulintransferrin-sodium selenite (combination of insulin, transferrin, and selenite) (Sigma-Aldrich Co., St Louis, MO, USA), 20 ng/mL recombinant EGF (Serotec, Raleigh, NC, USA), and 20 ng/mL recombinant bFGF (PeproTech, Rocky Hill, NJ, USA). The treated cells were sequentially cultured in a 24-well plate (Corning Incorporated, Corning, NY, USA) at a density of 4×10 3 cells/well. The medium containing the growth factors was replaced every 3 days. After the formation of the sphere (day 8), the cells were collected by centrifugation for further experiments.
Immunofluorescence
Sphere culture-enriched lung cancer cells (1×10 6 cells) were plated onto slides and incubated overnight. The slides were incubated with paraformaldehyde fixation (4%) for 30 minutes at 4°C. Then, the slides were blocked with FBS for 1 hour. The primary antibodies were applied at a 1:100 dilution for 1 hour at room temperature. Phosphate-buffered saline was used as the negative control to replace the primary antibody and to exclude nonspecific binding. The slides were treated with corresponding immunofluorescence-labeled secondary antibodies at 37°C for 15 minutes. Cell nucleus was stained with Hoechst 33342 and mounting medium was added before confocal microscopy examination. All the primary antibodies, including Oct4, NANOG, SOX2, KLF5, β-catenin, and MYC, were purchased from Abcam (Cambridge, UK). The immunofluorescence-labeled secondary antibodies and Hoechst 33342 were purchased from Vector Laboratories, Inc (Burlingame, CA, USA).
Quantitative real-time (rT) polymerase chain reaction assay Total cell RNA was isolated from the cells using the TRIzol ® RNA extraction kit (Thermo Fisher Scientific, Waltham, MA, USA). The obtained RNA was used to produce the cDNA by using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Polymerase chain reaction (PCR) was performed using specific primers of related genes (listed in Table 1 ) and a One Step SYBR ® PrimeScript™ RT-PCR kit (Takara, Dalian, People's Republic of China). The RT-PCR reaction was performed by utilizing the iQ5 real-time PCR detection system (Bio-Rad Laboratories Inc., Hercules, CA, USA). Furthermore, the expression of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was assessed simultaneously in all samples, which acted as an internal control. The relative gene expression was calculated by using the 2 -ΔΔCT analyzing method.
cell proliferation
After preparing the single cell suspension, 1×10 3 cells were seeded in 100 μL DMEM solution and then seeded in Drug Design, Development and Therapy 2015:9 colony formation assay Cells were suspended in 0.3% agar (Sigma-Aldrich Co.) in culture medium with or without the abovementioned Wnt pathway inhibitors and plated at a density of 1×10 5 cells/dish into a 10 cm dish, which was preloaded with a thin layer of 1.0% agar. Cells were kept in media during the assay and monitored for colony formation. After culturing for 7 days, the colony formation was observed. The clones were stained with trypan blue (Sigma-Aldrich Co.) to evaluate colony formation. The clones with more than 50 cells were collected and cells were counted. In a particular setting of colony formation, sphere culture-enriched cells were adjusted to a density of 450 cells/well and seeded into 96-well plates. After culturing the cells for 7 days, the colony formation was assessed by CCK-8 assay.
statistical analysis 
Results
enrichment of lcscs by colony formation and sphere culture
As shown in Figure 1A , the holoclone morphology could be found in SPC-A1 and PC9 cells, but not A549 cells, when performing the colony formation assay. The colony formation in PC9 and A549 cells was significantly more compared to SPC-A1 cells ( Figure 1B ; P0.05). Sphere culture was employed to enrich the LCSCs. A large-size cell sphere was found 7 days post-culture ( Figure 1C ). Cell counting results indicated that the number of SPC-A1 and PC9 cells was 55.0×10 3 cells/well and 30.2×10 3 cells/well, respectively, which indicates a significant difference ( Figure 1C ; P0.05). Meanwhile, the number of A549 cells (6.8×10 3 cells/well) was significantly lower compared to the SPC-A1 cells ( Figure 1C; P0.05) . The sphere culture-enriched lung cancer cells were then used for microvolume colony formation assay in a 96-well plate; greater colony formation was found in PC9 cells than in SPC-A1 cells, whereas no colonies were formed in A549 cells ( Figure 1D ).
classical Wnt signaling factor expression in lcscs
Immunofluorescence staining was employed to determine the cell phenotype. The pluripotent stem cell markers, such as NANOG, Oct4, KLF5, and SOX2, were positively expressed in SPC-A1 and PC9 cells. Moreover, we also found that the Wnt signaling components β-catenin and MYC were expressed on the sphere culture-enriched cells (Figure 2A and B) . 
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However, the immunofluorescence staining has not been illustrated the positive expressed stem cell markers in A549 cells (data known). In addition, the gene transcription of NANOG, Oct4, KLF5, SOX2, and Wnt signaling pathway factors MYC, Wnt7α, FZD1, FZD10, LRP5, and CTNNB1 was verified using RT-PCR assay. Significant increased transcription of pluripotent stem cell markers and Wnt signaling components was found after sphere culture ( Figure 2C-E) .
cell survival analysis of Wnt signaling pathway inhibitors
We tested the effects of four different Wnt signaling inhibitors on the growth of sphere-cultured cells. The halfmaximal inhibitory concentrations (IC 50 s) of these inhibitors are shown in Table 2 . SLM ( Figure 3A ) and ICG-001 ( Figure 3B ) were used at micromole concentrations, while PP ( Figure 3C ) was used at a nanomole concentration. ( Figure 4A ). Gene transcription was also determined by utilizing the RT-PCR method, and decreased expression of NANOG, SOX2, Wnt7b, FZD1, LRP5, and CTNNB1 was discovered in all these cell lines ( Figure 4B ), whereas KLF5 was significantly increased in SPC-A1 ( Figure 4C ) and PC9 ( Figure 4D ) cells, and POU5f1 was significantly increased in A549 cells ( Figure 4E ).
Discussion
In the present study, we first enriched the LCSCs by colony formation and sphere culture, and confirmed the expression of pluripotent stem cell markers and Wnt signaling components MYC and β-catenin in LCSCs. Then, in order to verify the function of the Wnt signaling pathway in LCSCs and to seek therapeutic agents, four different kinds of Wnt signaling inhibitors were employed to test the anti-proliferation effect. We found that PP efficiently inhibits LCSC proliferation in vitro at a dose below 10 nM and might have the potential to be used as a novel therapeutic agent to achieve desired clinical outcome in lung cancer patients.
Furthermore, silibinin ( Figure 3D ) was used at a micromole concentration. The IC 50 of PP for sphere-cultured SPC-A1, A549, and PC9 was 10 nM, 0.44 nM, and 0.21 nM, respectively ( Figure 3 ).
anti-proliferation effect of PP by targeting Wnt signaling pathway
The lung cancer cells were cultured for colony formation and the cells were collected at day 5 and day 7 for cell counting. A significant decrease in cell proliferation after treated with 5 nM PP was found at the day 7 compared to the day 5 The Wnt/β-catenin signaling pathway is one of the most critical signaling transduction pathways in cell tumorigenesis, development, proliferation, and progression. 11 The Wnt/β-catenin signaling pathway has become a hot topic in tumor research. In recent years, Wnt/β-catenin signaling pathway study has developed to the stage of progenitor and stem cell maintenance in some adult individual tissues, such as blood, muscle, skin, gut, nervous system, and prostate. 12 We observed the expression of Wnt signaling components in enriched LCSCs from lung cancer cells. We found that the Wnt signaling inhibitors, including SLM, ICG-001, PP, and silibinin, can effectively inhibit the growth of LCSCs in vitro.
A great deal of study has been undertaken to discover compounds or drugs that could specifically target CSCs. Some compounds have been discovered that could effectively target LCSCs. SLM is the first reported drug that used to therapy the Coccidia parasites in chickens. SLM is a potassium channel inhibitor, which can target CSCs in tumors, such as those found in leukemia, breast cancer, and other cancers. 13 Wang suggested that SLM could also be used in the treatment of LCSCs.
14 ICG-001 is a β-catenin/CBP inhibitor that can bind to the N-terminus of CBP. ICG-001 can also effectively attenuate the survivin expression in tumors. 15 ICG-001 has shown the ability to kill CSCs in neuroblastoma cell lines 16 and hepatoblasts. 17 Silibinin, a naturally occurring flavonoid produced by milk thistle, possesses antioxidant and anti-inflammatory activities. 18 Wang et al showed that silibinin could inhibit the maintenance and proliferation of CSCs in colorectal tissues via GSK-3β-related pathways, 19 and it may be involved in a mechanism of Wnt signaling regulation. SLM, ICG-001, and silibinin were employed here for comparison with PP. We found sphere-cultured A549 and PC9 cells were sensitive to all the inhibitors, while sphere-cultured SPC-A1 cells were only sensitive to SLM and ICG-001. This may be attributed to the participation of Wnt/GSK-3β in regulation of LCSCs in the PC9 and A549 cells, but not in the SPC-A1 cells. Therefore, further studies are needed to assess the detailed pathway regulation in different lung cancer cell lines.
Moreover, all three of the inhibitors (SLM, ICG-001, and silibinin) were used at a micromole-level dose, while PP could work at a nanomole-level dose, which was significantly lower than those of SLM, ICG-001, and silibinin. PP is a quinoline-derived cyanine dye, which was officially approved by the FDA for its antihelminthic characteristics in the 1950s. 20 Some authors have reported PP to have a therapeutic function against animal-like protists, such as Cryptosporidium parvum, 21 Plasmodium falciparum, 22 and others. In recent years, a few studies proved that PP could delay or inhibit tumor cell proliferation in cancer models, including models of pancreatic cancer 23 and colon cancer. 24 PP has been used in clinic for about 50 years, but the pharmacological mechanisms are not yet fully clarified. However, in the last 10 years, more and more researchers have studied PP in tumor therapy. Saraswati et al 25 discovered that PP could inhibit the Wnt signaling transduction pathway by activating casein kinase 1α (CK-1α). Wnt signaling-related proteins or genes have been studied in recent years with formation assay, including the expression of MYC protein and the activity of TOP-luciferase. 6 In vivo, Wnt signaling pathway inhibitors were examined employing classic Xenopus secondary axis formation analysis. 26 Gao et al 27 found that CK-1α could be directly targeted and activated by PP. What is known so far is that CK-1α is a critical kinase that can phosphorylate β-catenin. Further studies to verify expression levels of CK-1α could determine whether it is a target protein of PP in LCSCs.
Conclusion
PP was found to be able to selectively kill LCSCs and showed effective anti-tumor proliferation activity in vitro. However, further studies on decreasing the toxicity of PP and determining the target protein and signaling pathway should be performed before PP can be considered a therapeutic agent in lung adenocarcinoma.
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